• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

November 2, 2022

Finerenone May Protect Patients With Chronic Kidney Disease From Pneumonia-Related Severe Adverse Events

Author(s):

Erin Hunter, Assistant Editor

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

Finerenone may reduce the adverse events (AEs) associated with pneumonia and COVID-19 in patients with chronic kidney disease (CKD) and type 2 diabetes, according to the authors of a recent study published in JAMA Network Open. The results suggest that finerenone can modulate anti-inflammatory mechanisms that defend against severe AEs.

“We propose that a combination of factors, including improvements in pulmonary inflammation and fibrosis, coupled with upregulation of ACE2 expression and amelioration of right-heart pressure and pulmonary congestion, are likely to lead to an improved pulmonary environment that is less susceptible to a propagation of pulmonary infection and inflammation,” wrote the study authors.

Patients with CKD have a 2-fold greater risk of pneumonia compared to those without CKD. Patients often experience pneumonia as a morbidity that is independent of other morbidities, such as diabetes, cardiovascular disease, asthma, and chronic obstructive pulmonary disease. Patients with CKD who also contract pneumonia have been shown to have a greater risk of hospitalization, mortality, and cardiovascular AEs.

Finerenone is a selective and nonsteroidal mineralocorticoid receptor antagonist (MRA), a class of drug which lessens pulmonary inflammation and may also protect against COVID-19, according to some clinicians. To investigate this further, investigators evaluated the potential for finerenone to protect against AEs associated with pneumonia and COVID-19 in patients with CKD and type 2 diabetes.

Investigators gathered data for this secondary analysis from the FIDELITY study, comprised of the FIDELIO-DKD and FIGARO-DKD studies. They evaluated incidence rate of AEs from pneumonia or COVID-19 in 12,999 patients who either received finerenone or placebo.

After analysis of the data, the investigators found that the occurrence of pneumonia-associated AEs were significantly lower in patients who took finerenone.

“There was also a lower risk of COVID-19 AEs among patients who received finerenone,” study authors wrote. “Fineronone was consistently associated with reduced risk of pneumonia and serious pneumonia vs placebo.”

However, there are limitations in this study. First, patients could have been misdiagnosed as having pneumonia when it could have been heart failure or pulmonary edema. Additionally, antigen and polymerase chain reaction testing for COVID-19 was not widely available at the time of the study.

MRAs function by blocking the mineralocorticoid receptor; in turn, this may create an anti-inflammatory response and reduce the risk of pneumonia and COVID-19-associated AEs.

MRAs can also block the accumulation of active macrophages, which can result from COVID-19 and can lead to pulmonary tissue damage. Further, this accumulation may increase expression of angiotensin-converting enzyme 2, which is the functional host receptor for the SARS-CoV-2 spike protein. As a result, MRAs may protect against lung damage.

“Mineralocorticoid receptor blockade with finerenone was associated with protection against pneumonia and COVID-19 adverse events (AEs) in patients with type 2 diabetes and CKD,” study authors wrote. “However, further clinical studies may be warranted.”

Reference

Pitt, Bertram, Agarwal, Rajiv, Anker, Stefan, et al. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease. JAMA Netw Open. 2022;5(10):e2236123. doi:10.1001/jamanetworkopen.2022.36123

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
1 expert in this video
1 expert in this video
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Related Content
Advertisement
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
Visualization of CAR T-cell among red blood cells | Image Credit: © Olha - stock.adobe.com
July 1st 2025

Cilta-Cel Spurs Remission Milestone—But Is It a Cure?

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
Visualization of CAR T-cell among red blood cells | Image Credit: © Olha - stock.adobe.com
July 1st 2025

Cilta-Cel Spurs Remission Milestone—But Is It a Cure?

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.